News

The improved ArkScore interprets the complex results of a molecular diagnostic test and presents an optimal course of treatment. This simplification allows each physician to quickly understand how treatment options are affected by the patient’s profile, presence of specific organisms, and resistance genes.

Arkstone Medical Solutions has filed Provisional U.S. Patent Applications covering technologies that aid physicians in making educated and informed decisions for patient care. These systems are already in use on the renowned Arkstone Report, which analyzes molecular diagnostic lab results and guides physicians with pinpoint interpretations and recommendations.

AMS Onsite, the leading infection control and prevention (ICP) practice for America's long-term care facilities, today announced a partnership with Arkstone Medical Solutions, a pioneer in infectious disease treatment guidance. The integration allows AMS Onsite to leverage Arkstone’s proprietary report and targeted treatment recommendations, further reducing antibiotic resistance and infections and improving health outcomes for residents in long-term care and skilled nursing facilities.

Arkstone's OneChoice technology automatically analyzes many factors like specimen source, organisms and genes detected, patient age and gender, and diagnosis, to arrive at a targeted precision-guided treatment recommendation. By incorporating which antibiotics the patient may be allergic to, the recommendations are now even more tailored to the specific patient's needs.

The new COVID-19 Pandemic Alert section incorporates infection statistic information from Johns Hopkins University, specific to the location of the patient, to help keep providers informed of potential increases in infection rates. While no treatment or vaccine is yet available, the Arkstone Report continues to assist providers in making informed care decisions by including the latest treatment information at the time of the lab test.